2024-513258-31-00
Active, not recruiting
Phase 1
A study to find how well VES001 works and how safe it is in participants with GRN -frontotemporal dementia (GRN-FTD) showing no symptoms
Vesper Bio ApS, Vesper Bio ApS1 site in 1 country3 target enrollmentStarted: October 28, 2024Last updated:
Overview
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Vesper Bio ApS, Vesper Bio ApS
- Enrollment
- 3
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Mads Kjolby
Scientific
Vesper Bio ApS
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
SAD and MAD study of VES0012023-505847-38-00Insusense ApS, Insusense ApS78
Not yet recruiting
Phase 1
An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.2023-505185-28-00F. Hoffmann-La Roche AG52
Recruiting
Phase 1
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)2023-507611-35-00Generate Biomedicines Inc.70
Completed
Phase 1
A Phase 1 Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Mild to Moderate Crohn's Disease2022-502241-99-00Exeliom Biosciences50
Not yet recruiting
Phase 1
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).2024-515074-26-00AgomAb Therapeutics64